📰 India’s Pharma Exports Hit Record $31.11 Billion in FY26 Even With Global Hurdles

India’s drug sector reached a major goal in FY26. Exports hit a record $31.11 billion during the year. This result shows 2.1% growth over the previous year. Success came even with global problems and a 23% drop in March 2026. These results show industry strength and flexibility. 🌍💊

📊 Key Highlights
- Strong Core Segment: Drug formulas and biologicals led exports at 74.2% or $23.08 billion.
- Vaccine Boom: Vaccines were the fastest-growing group with sales rising 26.4% to $1.5 billion.
- Market Diversification: Sales grew in Africa by 13% and Oceania rose by 11.5% and Latin America saw 10% growth.
- Currency Advantage: A weaker rupee helped push export value past ₹2.86 lakh crore.

⚠️ Challenges faced
- US & China Slowdown: Exports fell in these markets after stock levels grew and demand fell.
- Geopolitical Disruptions: Fighting in West Asia hurt shipping and raised freight costs.
- Regulatory Pressure: USFDA checks and new tariffs caused worry for many firms.
- Import Dependence: India gets 74% of active ingredients from China which creates risk.

🚀 Future Outlook

India’s drug market is worth $60 billion today. Experts think the market will reach $130 billion by 2030. Firms now focus on high-value items like biosimilars, specialty drugs, and complex generics. The government PLI scheme supports this shift in production.

The Indian pharma sector continues to grow its global presence. It adapts to new market trends and discovers ways to grow.